HIV and HCC in Africa: The H2A Consortium

非洲的艾滋病毒和肝癌：H2A 联盟

• 批准号: 10471411
• 负责人: Gregory D Kirk
• 金额: $ 99.06万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-09 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10471411
• 关键词: Address; Adopted; Advocate; Africa; Africa South of the Sahara; African; Age; Aging; Award; Biological Markers; Cause of Death; Chronic; Clinical; Clinical Data; Clinical Research; Collaborations; Country; Data; Development; Epidemiology; Etiology; Foundations; Funding; Goals; HIV; HIV Infections; Hepatitis B; Hepatitis B Infection; Hepatitis B Therapy; Hepatitis B Virus; Hepatitis C virus; Hepatocarcinogenesis; Human; Immune response; Incidence; Individual; Infection; Infrastructure; Intercept; Interruption; Intervention; Investigation; Investments; Lead; Liver; Liver Fibrosis; Liver diseases; Malignant Neoplasms; Measurement; Medical; Mentors; Monitor; Oncogenes; Pathway interactions; Patients; Persons; Pilot Projects; Population; Population Research; Praziquantel; Prevention strategy; Primary carcinoma of the liver cells; Process; Prospective cohort; Research; Research Design; Research Infrastructure; Research Personnel; Research Project Grants; Resource-limited setting; Resources; Risk; Risk Factors; Schistosoma mansonii infection; Senegal; Serum Albumin; Translational Research; Uganda; United States National Institutes of Health; Universities; Viral hepatitis; antiretroviral therapy; base; biobank; biomarker discovery; career development; chronic infection; co-infection; cohort; curative treatments; data quality; design; effective therapy; high risk; improved; innovation; mortality; multidisciplinary; novel; novel marker; predictive marker; prevent; prospective; recruit; response; scale up; screening; success; translational study; treatment strategy

Hepatocellular carcinoma (HCC) is a very common and lethal cancer in Africa, and as patients with HIV live longer, the HCC burden may increase. In prior studies, our team identified chronic infection with hepatitis B and C viruses (HBV, HCV), HIV and Schistosomiasis mansoni as independent risk factors for HCC. Compared to the US, HCC in sub-Saharan Africa occurs at younger age and more advanced stage with survival of only months. Proposed is an East and West African partnership between colleagues at Makerere University in Uganda, Fann University in Senegal and Johns Hopkins University focused on HIV and hepatocellular carcinoma (HCC) in Africa: The H2A Consortium. Building on long-standing collaborative research, mentoring and clinical activities in both countries, our overarching goal is to reduce the heavy burden of HCC in sub- Saharan Africa. We advocate investigating cancer interception strategies using appropriate medical treatments to interrupt or reverse the impact of these HCC-causing infections. We will accomplish this objective by developing local capacity and performing important research. Consortium activities are designed to enhance both the clinical, population and translational research infrastructure and individual African investigator capacity to conduct high-level, collaborative investigation of HIV, chronic infections and HCC. First, we will form a large, prospective cohort of HBV and HBV/HIV co-infected persons to define who needs HBV treatment, determine clinical responses, and characterize breakthrough HCC, while investigating novel biomarkers. To understand our data demonstrating synergistic interaction between chronic HBV and Sm infections, we will examine HBV clinical and immunological responses in the periphery and the liver in response to Sm treatment. HIV is investigated as a key modifier of these relationships in both projects. Integrated within our scientific agenda, early-stage African investigators will be provided mentoring and career development support while conducting a collaborative pilot project leveraging Consortium resources. The impact of our integrated research and capacity development activities will be establishment of the H2A Consortium as partnered Centers of Excellence on HIV and HCC in East and West Africa.

肝细胞癌 (HCC) 是非洲一种非常常见且致命的癌症，随着艾滋病毒患者的生存 时间越长，HCC 负担可能会增加。在之前的研究中，我们的团队发现了乙型肝炎的慢性感染 C 病毒（HBV、HCV）、HIV 和曼氏血吸虫病是 HCC 的独立危险因素。比较的 与美国相比，撒哈拉以南非洲地区的 HCC 发病年龄更小，阶段更晚期，生存期仅为 几个月。提议在马凯雷雷大学的同事之间建立东非和西非伙伴关系 乌干达、塞内加尔范恩大学和约翰·霍普金斯大学专注于艾滋病毒和肝细胞 非洲癌症 (HCC)：H2A 联盟。建立在长期合作研究、指导的基础上 以及两国的临床活动，我们的首要目标是减轻亚裔 HCC 的沉重负担 撒哈拉非洲。我们主张使用适当的医疗方法研究癌症拦截策略 中断或扭转这些引起 HCC 的感染的影响。我们将通过以下方式实现这一目标 发展当地能力并开展重要研究。联盟活动旨在增强 临床、人口和转化研究基础设施以及非洲个体研究者的能力 对艾滋病毒、慢性感染和肝癌进行高水平的协作调查。首先，我们要组建一个庞大的、 HBV 和 HBV/HIV 合并感染者的前瞻性队列，以确定谁需要 HBV 治疗，确定 临床反应，并描述突破性 HCC 的特征，同时研究新的生物标志物。要了解 我们的数据表明慢性 HBV 和 Sm 感染之间存在协同相互作用，我们将检查 HBV 外周和肝脏对 Sm 治疗的临床和免疫反应。艾滋病毒是 作为这两个项目中这些关系的关键修正因素进行了研究。融入我们的科学议程， 早期阶段的非洲调查人员将在开展研究工作时获得指导和职业发展支持 利用联盟资源的协作试点项目。我们综合研究和的影响 能力发展活动将是建立 H2A 联盟作为合作中心 东非和西非艾滋病毒和肝癌方面的卓越成就。